| Literature DB >> 34100012 |
Lisiena Hysenaj, Samantha Little, Kayla Kulhanek, Oghenekevwe M Gbenedio, Lauren Rodriguez, Alan Shen, Jean-Christophe Lone, Leonard C Lupin-Jimenez, Luke R Bonser, Nina K Serwas, Kriti Bahl, Eran Mick, Jack Z Li, Vivianne W Ding, Shotaro Matsumoto, Mazharul Maishan, Camille Simoneau, Gabriela Fragiadakis, David M Jablons, Charles R Langelier, Michael Matthay, Melanie Ott, Matthew Krummel, Alexis J Combes, Anita Sil, David J Erle, Johannes R Kratz, Jeroen P Roose.
Abstract
SARS coronavirus-2 (SARS-CoV-2) is causing a global pandemic with large variation in COVID-19 disease spectrum. SARS-CoV-2 infection requires host receptor ACE2 on lung epithelium, but epithelial underpinnings of variation are largely unknown. We capitalized on comprehensive organoid assays to report remarkable variation in SARS-CoV-2 infection rates of lung organoids from different subjects. Tropism is highest for TUBA- and MUC5AC-positive organoid cells, but levels of TUBA-, MUC5A-, or ACE2-positive cells do not predict infection rate. We identify surface molecule Tetraspanin 8 (TSPAN8) as novel mediator of SARS-CoV-2 infection, which is not downregulated by this specific virus. TSPAN8 levels, prior to infection, strongly correlate with infection rate and TSPAN8-blocking antibodies diminish SARS-CoV-2 infection. We propose TSPAN8 as novel functional biomarker and potential therapeutic target for COVID-19.Entities:
Year: 2021 PMID： 34100012 PMCID： PMC8183007 DOI： 10.1101/2021.06.01.446640
Source DB: PubMed Journal: bioRxiv